SCHEMBL640183

SCHEMBL640183

COc1ccc(S(=O)(=O)n2c(=O)n(C(C(=O)N3CCC[C@@H](NC4CNC4)C3)c3ccccc3)c3cc(C#N)ccc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
CCR6 P51684 3/20 0.38
MMP1 P03956 3/20 0.36
MMP9 P14780 3/20 0.36
MMP13 P45452 3/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
CHRM5 P08912 1/20 0.35
PKM P14618 1/20 0.34
POLB P06746 1/20 0.33
MGLL Q99685 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KCNQ1 P51787 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10007670 1.00 HCRTR1 (0.40) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL642339 1.00 HCRTR1 (0.40) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL10008516 0.96 CCR6 (0.38) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL642759 0.96 CCR6 (0.38) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL643070 0.92 CCR6 (0.40) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL643069 0.92 CCR6 (0.40) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL643292 0.92 CCR6 (0.40) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL641318 0.91 CCR6 (0.39) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL640094 0.91 CCR6 (0.39) HCRTR1HCRTR2CCR6MMP1MMP9
SCHEMBL640093 0.91 CCR6 (0.39) HCRTR1HCRTR2CCR6MMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A HCRTR1 951/4885HCRTR2 641/4885CCR6 4653/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A HCRTR1 951/4885HCRTR2 641/4885CCR6 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.